top of page
US FDA grants Qualified Infectious Disease Product designation to Venus Remedies’ VRP-034, a novel polymyxin B formulation
Developed by Venus Medicine Research Centre (VMRC), the R&D division of Venus Remedies, VRP-034 is a novel supramolecular cationic (SMC) formulation of polymyxin B sulphate
Apr 173 min read
Venus Remedies secures exclusive in-licensing rights from Infex Therapeutics to develop and commercialise MET-X in India
Venus Remedies will commence with a Phase I trial involving volunteers in India. MET-X is Infex Therapeutics’ broad spectrum MBL-inhibitors.
Feb 254 min read
Venus Remedies gets marketing authorisation for anticoagulant ‘Enoxaparin’ from Indonesia
Venus Remedies received marketing authorisation from Indonesia for Enoxaparin in pre-filled syringes across all major strengths
Feb 102 min read
Venus Remedies secures EU GMP renewal from Infarmed, strengthens European market presence
Commitment to stringent European standards reinforces Venus Remedies’ leadership in antibiotics and oncology manufacturing
Jan 213 min read
Venus Remedies secures GMP certification from Moldova Ministry of Health for antibiotic-carbapenem facility
Venus Remedies Ltd received GMP certification from the Ministry of Health of Moldova for its antibiotic-carbapenem manufacturing facility
Dec 31, 20242 min read
Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine
Ukrainian approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Mar 18, 20243 min read
Venus Remedies gets huge global acclaim with UNICEF GMP approval
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended to supply cephalosporin dry powder to UNICEF.
Mar 11, 20242 min read
bottom of page